Rivermead Rehabilitation Centre Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2001
NCT01610713
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Alternative names

Rivermead Rehabilitation Centre, Oxford.

Active Ingredients

Drugs in Phase 3 Trials (1)

tetrahydrocannabinol (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1